Cambridge Clinical Laboratories

What Cambridge Clinical Laboratories does

Cambridge Clinical Laboratories (CCL) is a UK-based personalised healthcare testing laboratory headquartered in Cambridge, with UKAS accreditation for medical testing services. The company specialises in oncology diagnostics, virology, hereditary cancer testing, companion diagnostics, and pharmacogenetic testing, employing molecular diagnostics and next-generation sequencing as its underlying technology platforms. Its product portfolio spans screening, aggressiveness assessment, treatment-guidance, and surveillance tests across multiple tumour types, including prostate, breast, lung, bladder, bowel, stomach, and thyroid cancers, alongside a 31-gene hereditary cancer panel and tests for biomarkers such as HER2, BRCA, PIK3CA, PD-L1, EGFR, KRAS, and BRAF.

CCL's product strategy is built on curating and distributing a portfolio of clinically validated, third-party developed proprietary tests — notably Bladder EpiCheck (Nucleix), EarlyCDT Lung, Stockholm3 (Karolinska Institutet), Proclarix (Proteomedix), and Prostatype (Prostatype Genomics) — rather than developing tests in-house. The business operates on a B2B2C model: revenue is generated through per-test fees (e.g., FIT at £40 per test directly) billed primarily to healthcare professionals (GPs, consultant surgeons, urologists) and partner private clinics (Goodbody Clinic, Innermost Healthcare, Remedi Health), with NHS engagement via trials such as the Bladder EpiCheck study at Western General Hospital Edinburgh. Most tests are not sold directly to patients; instead, patients access them through healthcare provider referrals or partner clinic platforms.

In April 2025, CCL was acquired by Source BioScience UK Ltd, a provider of genomic services and histopathology diagnostics, integrating CCL's molecular diagnostics capability into a broader laboratory services platform spanning R&D through clinical trial support. Following the acquisition, CCL continues to operate as a specialty cancer testing provider within Source BioScience's portfolio.

Name

Cambridge Clinical Laboratories

Legal name

Cambridge Clinical Laboratories Ltd

Website

https://camclinlabs.co.uk

Company type

Private

Founded year

2005

Operating status

Acquired

Headcount range

11–50 employees

Short description

Cambridge Clinical Laboratories is a UKAS-accredited Cambridge-based specialty diagnostics laboratory providing oncology, hereditary cancer, companion diagnostics, and virology testing services to UK healthcare professionals and partner private clinics, now operating as part of Source BioScience.

Ownership category

akta.pro rank

Product category

Clinical Diagnostic Laboratory Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Reference & Esoteric Testing Laboratories (HLAFAMAJ)

akta.pro secondary industries

Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Clinical Chemistry & Immunoassay Laboratories (HLAFAMAB), Central Laboratory Services (Core Lab Operations) (HLAGAEAA)

Keywords

• Clinical diagnostics
• Oncology testing
• Molecular diagnostics
• Genetic testing
• Virology services

Headquarters

HQ city

Cambridge

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Laboratory Diagnostic Testing Services: CCL provides UKAS accredited personalised healthcare testing services including oncology, virology, pharmacogenetic, and hereditary cancer testing to healthcare professionals and organizations. Revenue generated through test fees charged for diagnostic services.
2. Clinical Testing: Following acquisition by Source BioScience in April 2025, CCL now operates as part of Source BioScience's complete laboratory service portfolio, supporting clinical trials and diagnostics from R&D through preclinical and clinical stages.

Pricing tiers

Go-to-market motion1 record

Distribution channels5 records

Marketing channels4 records

Core offering

Cambridge Clinical Laboratories is a UKAS accredited clinical diagnostic laboratory that provides personalised healthcare testing services to healthcare professionals and organisations. Its core offering is a portfolio of oncology, hereditary cancer, companion diagnostic, and virology tests, including proprietary and partner-developed assays such as Bladder EpiCheck, EarlyCDT Lung, Stockholm3, Proclarix, Prostatype, FIT testing, and a 31-gene hereditary cancer panel. Tests are ordered by GPs, consultants, and specialist urologists and delivered through partner clinics and NHS engagements.

Product overview

Cambridge Clinical Laboratories (CCL) is a UK-based personalised healthcare testing laboratory offering UKAS accredited testing services. The company operates as a platform of specialized cancer and diagnostic testing services rather than a single unified product. The portfolio includes: oncology testing services (prostate, breast, lung, bladder, bowel, stomach, thyroid cancers); hereditary cancer genetic testing panels; companion diagnostics for treatment guidance; and specialized tests including EarlyCDT Lung, Stockholm3, Proclarix, Prostatype, Bladder EpiCheck, and FIT testing. The company was acquired by Source BioScience in April 2025.

Differentiator

Problem solved

Functional benefit

Products and services

• Oncology Testing Services
• Bladder EpiCheck

Quantifiable outcome

• 99.3% NPV for bladder cancer detection
• +3 more outcomes

Named customers4 records

Segments2 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• Source BioScience UK LtdcoreStrategic or Co-development Partner · 1 April 2025In April 2025, Source BioScience acquired Cambridge Clinical Laboratories. The acquisition complements Source BioScience's established capabilities in genomics and multi-omics, expanding its clinical offering to provide a complete laboratory service portfolio from R&D through clinical stages.
• NucleixcoreTechnology or IntegrationNucleix developed Bladder EpiCheck, a urine test for bladder cancer detection. CCL offers this test in the UK as part of their bladder cancer portfolio, with ongoing NHS trial collaboration.
• Prostatype GenomicscoreTechnology or IntegrationProstatype Genomics developed Prostatype, a genetic test for determining prostate cancer aggressiveness. CCL is an authorized provider of this test in the UK.
• ProteomedixcoreTechnology or IntegrationProteomedix developed Proclarix, a protein-based blood test for prostate cancer risk assessment in the PSA grey zone. CCL offers this test in the UK.
• Karolinska InstitutetcoreTechnology or IntegrationKarolinska Institutet developed Stockholm3, an advanced screening test for aggressive prostate cancer. Validated on over 75,000 men, the test is included in European and American prostate cancer guidelines.
• Western General Hospital EdinburghcoreStrategic or Co-development PartnerCCL collaborating with Nucleix and Dr Mariappan at Western General Hospital Edinburgh on NHS trial for Bladder EpiCheck, commencing Summer 2023 to evaluate replacing up to half of surveillance cystoscopies.
• Radboud University Medical CentreminorStrategic or Co-development PartnerFirst hospital to make Bladder EpiCheck standard-of-care for bladder cancer patients. Professor Witjes reduces cystoscopies by alternating with Bladder EpiCheck.
• Goodbody CliniccoreChannel Partner/ Reseller/ DistributorGoodbody Clinic is a partner healthcare provider offering CCL tests including FIT, EarlyCDT Lung, Stockholm3, and Proclarix through their online platform and clinic locations.
• Innermost HealthcarecoreChannel Partner/ Reseller/ DistributorInnermost Healthcare offers multiple CCL tests (EarlyCDT, Bladder EpiCheck) at their Cardiff clinic and provides home visit phlebotomy services UK-wide.
• Prostate MattersminorGTM or Marketing PartnerProstate Matters is a not-for-profit organization that has endorsed Stockholm3 and provides information about the test on their website.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Oncologica UK: Cambridge-based molecular oncology diagnostics lab offering NGS-based cancer profiling and companion diagnostics, directly comparable to CCL in geography, market, and specialized cancer testing focus.
• The Doctors Laboratory (TDL): Large UK private pathology/reference laboratory serving clinicians and private healthcare providers, overlapping strongly with CCL's B2B lab-testing model for the private and NHS sectors.
• Randox Laboratories: UK diagnostics company offering clinical and cancer-related testing to healthcare providers, comparable to CCL in market, testing menu, and B2B distribution.

Broad incumbents

• SYNLAB UK & Ireland: Major clinical laboratory network providing diagnostic testing to NHS and private providers across the UK, overlapping with CCL's core lab services at far larger scale.
• Exact Sciences: Global cancer screening and diagnostics company (Cologuard, Oncotype); competes in the cancer early-detection and prognostic testing category CCL operates in.
• Eurofins Scientific: Global testing and clinical diagnostics group offering broad laboratory services, a much larger incumbent overlapping CCL's clinical lab and companion diagnostics activities.

Others

• Source BioScience: CCL's parent company providing genomics, histopathology and clinical trial support; adjacent and now the owner rather than a direct market competitor.

Emerging players

• Nonacus: UK genomics company developing liquid biopsy and cancer detection assays including bladder cancer, overlapping with CCL's oncology molecular testing niche.
• GRAIL: Multi-cancer early detection company whose blood-based screening mission overlaps with CCL's early-detection oncology test portfolio.

Regional players

• Medichecks: UK consumer-facing diagnostic testing provider using accredited labs; overlaps with CCL's UK health-testing market though via a more direct-to-consumer model.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/camclinlabs

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cambridge Clinical Laboratories